

# Hussein R Al-Khalidi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9897991/publications.pdf>

Version: 2024-02-01

68  
papers

5,776  
citations

159358

30  
h-index

91712

69  
g-index

69  
all docs

69  
docs citations

69  
times ranked

6927  
citing authors

#	ARTICLE	IF	CITATIONS
1	Renal function and coronary bypass surgery in patients with ischemic heart failure. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 663-672.e3.	0.4	5
2	Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1890-1899.e4.	0.4	5
3	Perioperative Outcomes of Thymectomy in Myasthenia Gravis: A Thoracic Surgery Database Analysis. Annals of Thoracic Surgery, 2022, 113, 904-910.	0.7	11
4	The prospective randomized trial of the optimal evaluation of cardiac symptoms and revascularization: Rationale and design of the PRECISE trial. American Heart Journal, 2022, 245, 136-148.	1.2	13
5	Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Medicine in Ischemic Cardiomyopathy: The STICH Randomized Clinical Trial. Circulation, 2022, 145, 819-828.	1.6	7
6	MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial. Circulation, 2022, 145, 906-915.	1.6	12
7	Use of Lipid-, Blood Pressure, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. JAMA Network Open, 2022, 5, e2148030.	2.8	30
8	Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial. Circulation, 2022, 145, 796-804.	1.6	44
9	Quality of life impact and recovery after ureteroscopy and stent insertion: insights from daily surveys in STENTS. BMC Urology, 2022, 22, 53.	0.6	5
10	Influence of atrial fibrillation type on outcomes of ablation vs. drug therapy: results from CABANA. Europace, 2022, 24, 1430-1440.	0.7	9
11	Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants. JAMA Network Open, 2022, 5, e2214321.	2.8	4
12	Study to Enhance Understanding of Stent-Associated Symptoms: Rationale and Study Design. Journal of Endourology, 2021, 35, 761-768.	1.1	9
13	Association Between Sex and Treatment Outcomes of Atrial Fibrillation Ablation Versus Drug Therapy. Circulation, 2021, 143, 661-672.	1.6	47
14	Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure. Circulation, 2021, 143, 1377-1390.	1.6	223
15	Treatment-Related Changes in Left Atrial Structure in Atrial Fibrillation: Findings From the CABANA Imaging Substudy. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008540.	2.1	9
16	Prevention of Urinary Stones With Hydration (PUSH): Design and Rationale of a Clinical Trial. American Journal of Kidney Diseases, 2021, 77, 898-906.e1.	2.1	19
17	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. Circulation, 2021, 144, 74-84.	1.6	34
18	Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities. Journal of the American College of Cardiology, 2021, 78, 126-138.	1.2	28

#	ARTICLE	IF	CITATIONS
19	Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 314.	3.8	68
20	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. <i>American Heart Journal</i> , 2020, 220, 41-50.	1.2	22
21	Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the Implementation of a randomized controlled trial to improve treatment with oral Anticoagulants in patients with Atrial Fibrillation (IMPACT-AFib). <i>American Heart Journal</i> , 2020, 229, 110-117.	1.2	15
22	Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. <i>Europace</i> , 2020, 22, 1337-1344.	0.7	21
23	Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3105-3118.	1.2	119
24	Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5. <i>Europace</i> , 2020, 22, 1026-1035.	0.7	26
25	Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era. <i>American Heart Journal</i> , 2020, 223, 87-97.	1.2	17
26	Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. <i>New England Journal of Medicine</i> , 2019, 381, 739-748.	13.9	186
27	Burden of medical comorbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019, 21, 373-381.	2.9	12
28	Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1261.	3.8	953
29	Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial. <i>International Journal of Cardiology</i> , 2019, 291, 36-41.	0.8	3
30	Stress Testing Versus CT Angiography in Patients With Diabetes and Suspected Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 893-902.	1.2	51
31	Impact of Intubation Time on Survival following Coronary Artery Bypass Grafting: Insights from the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 1256-1263.	0.6	1
32	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. <i>American Heart Journal</i> , 2018, 199, 51-58.	1.2	9
33	Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. <i>European Heart Journal</i> , 2018, 39, 2942-2955.	1.0	181
34	Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design. <i>American Heart Journal</i> , 2018, 199, 192-199.	1.2	107
35	Cardiac-Specific Conversion Factors to Estimate Radiation Effective Dose From Dose-Length Product in Computed Tomography. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 64-74.	2.3	111
36	Society of Thoracic Surgeons Risk Score and EuroSCORE-2 Appropriately Assess 30-Day Postoperative Mortality in the STICH Trial and a Contemporary Cohort of Patients With Left Ventricular Dysfunction Undergoing Surgical Revascularization. <i>Circulation: Heart Failure</i> , 2018, 11, e005531.	1.6	26

#	ARTICLE	IF	CITATIONS
37	Delays in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients Presenting With Cardiogenic Shock. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1824-1833.	1.1	42
38	Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. <i>Open Heart</i> , 2018, 5, e000752.	0.9	1
39	Association of Rapid Care Process Implementation on Reperfusion Times Across Multiple ST-Segmentâ€Elevation Myocardial Infarction Networks. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	44
40	Value of Cardiovascular Magnetic Resonance Imagingâ€Derived Baseline Left Ventricular Ejection Fraction and Volumes for Precise Risk Stratification of Patients With Ischemic Cardiomyopathy. <i>JAMA Cardiology</i> , 2017, 2, 577.	3.0	5
41	Identification of Patients With Stable Chest Pain Deriving Minimal Value From Noninvasive Testing. <i>JAMA Cardiology</i> , 2017, 2, 400.	3.0	80
42	Regional left ventricular function does not predict survival in ischaemic cardiomyopathy after cardiac surgery. <i>Heart</i> , 2017, 103, 1359-1367.	1.2	13
43	Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. <i>Europace</i> , 2017, 19, 132-138.	0.7	32
44	Impact of Regional Systems of Care on Disparities in Care Among Female and Black Patients Presenting With STâ€Segmentâ€Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	18
45	Safety of coronary CT angiography and functional testing for stable chest pain in the PROMISE trial: A randomized comparison of test complications, incidental findings, and radiation dose. <i>Journal of Cardiovascular Computed Tomography</i> , 2017, 11, 373-382.	0.7	24
46	Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF). <i>American Heart Journal</i> , 2017, 192, 38-47.	1.2	5
47	Impact of Diabetes Mellitus on the Evaluation of Stable Chest Pain Patients: Insights From the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	12
48	A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. <i>Lancet, The</i> , 2017, 390, 1737-1746.	6.3	154
49	A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale. <i>American Heart Journal</i> , 2016, 176, 107-113.	1.2	8
50	Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. <i>New England Journal of Medicine</i> , 2016, 374, 1511-1520.	13.9	731
51	Regional Systems of Care Demonstration Project. <i>Circulation</i> , 2016, 134, 365-374.	1.6	81
52	The RENEW Trial. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1576-1585.	1.1	107
53	Relationship of Right Ventricular Size and Function with Respiratory Status in Duchenne Muscular Dystrophy. <i>Pediatric Cardiology</i> , 2016, 37, 878-883.	0.6	12
54	Clinical predictors and outcomes of patients with left ventricular thrombus following ST-segment elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 365-373.	1.0	21

#	ARTICLE	IF	CITATIONS
55	Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. <i>JACC: Heart Failure</i> , 2015, 3, 159-167.	1.9	30
56	Primary Prevention Implantable Cardioverter-Defibrillators in Older Racial and Ethnic Minority Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 145-151.	2.1	14
57	Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2015, 372, 1291-1300.	13.9	1,179
58	Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction. <i>European Heart Journal</i> , 2015, 36, 2733-2741.	1.0	52
59	Comparison of right and left ventricular function and size in Duchenne muscular dystrophy. <i>European Journal of Radiology</i> , 2015, 84, 1938-1942.	1.2	20
60	Importance of Angina in Patients With Coronary Disease, Heart Failure, and Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2092-2100.	1.2	48
61	The MitraClip and survival in patients with mitral regurgitation at high risk for surgery: A propensity-matched comparison. <i>American Heart Journal</i> , 2015, 170, 1050-1059.e3.	1.2	72
62	Influence of Baseline Characteristics, Operative Conduct, and Postoperative Course on 30-Day Outcomes of Coronary Artery Bypass Grafting Among Patients With Left Ventricular Dysfunction. <i>Circulation</i> , 2015, 132, 720-730.	1.6	72
63	Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2015, 36, 1264-1272.	1.0	144
64	Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2209.	3.8	35
65	PROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial. <i>American Heart Journal</i> , 2014, 167, 796-803.e1.	1.2	104
66	Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 793-799.	2.1	45
67	Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. <i>Lancet, The</i> , 2014, 384, 1187-1195.	6.3	123
68	Assessment of Myocardial Contractile Function Using Global and Segmental Circumferential Strain following Intracoronary Stem Cell Infusion after Myocardial Infarction: MRI Feature Tracking Feasibility Study. <i>ISRN Radiology</i> , 2013, 2013, 1-6.	1.2	4